We are testing a new medication called Sage-319 to see how safe it is and how the body handles it. This study helps us understand its effects and potential use in future treatments.
Health conditions and diseases that the clinical trial is designed to study and treat.
GABAergic Signaling Disorders are conditions that involve problems with the brain's GABA neurotransmitter system, which can affect mood, coordination, and overall mental health. These disorders may lead to symptoms such as anxiety, balance issues, and cognitive difficulties.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.